Peringatan Keamanan

Readily accessible data regarding the toxicity of almasilate is not available.

Almasilate

DB13595

small molecule approved experimental

Deskripsi

Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids A27138.

Given that there are generally more widely available conventional antacids that are just as - if not more - effective than almasilate, almasilate products are only available in certain parts of Europe and/or Asia.

Struktur Molekul 2D

Berat 280.445
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Readily accessible data regarding the half-life of almasilate is not available.
Volume Distribusi The distribution of aluminum can occur in the bones, lungs, spleen, liver, kidney, nervous tissues, muscles, the blood itself, and the heart [F23]. The highest levels of aluminum in mammalian tissues are found in the skeleton, lungs, kidneys, spleen, thyroid, and parathyroid glands [F24]. Conversely, approximately half of the total magnesium in the body is distributed intracellularly in soft tissue and the other half is present in the bones [A32827]. Less than 1% of the total magnesium content is present in the blood [A32827]. In pregnant women, apparent volumes of distribution were evidently observed to range from 0.250 to 0.442 L/kg [A32827].
Klirens (Clearance) Readily accessible data regarding the clearance of almasilate is not available.

Absorpsi

In regards to aluminum-containing antacids like the aluminum-magnesium complex almasilate, it is reported that the bioavailability of ingested aluminum from such antacids is only between 0.01-1% L2620. Additionally, while the optimal absorption of magnesium appears to be in the small intestine and particularly in the ileum and jejunum, with some absorption in the colon, it is believed that the transfer of magnesium from blood to extravascular space is quick and efficient A32827.

Metabolisme

Once aluminum has entered the body, the mechanism by which it is metabolized is still not fully known F23. Conversely, magnesium balance in the body is predominantly managed via a balance between intestinal absorption, exchange with bone, and renal excretion A32840.

Rute Eliminasi

The routes of excretion of aluminum in the body are mainly from the kidneys, which account for 95% of the elimination F23. Magnesium is largely excreted in the urine A32840.

Interaksi Makanan

2 Data
  • 1. Take after a meal.
  • 2. Take with a full glass of water.

Interaksi Obat

967 Data
Atazanavir Almasilate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bosutinib Almasilate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefditoren The serum concentration of Cefditoren can be decreased when it is combined with Almasilate.
Dabigatran etexilate Almasilate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dabrafenib Almasilate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dasatinib Almasilate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delavirdine Almasilate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Erlotinib Almasilate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gefitinib Almasilate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Itraconazole Almasilate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ledipasvir Almasilate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate Almasilate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Pazopanib Almasilate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Riociguat Almasilate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levothyroxine Almasilate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tolevamer The risk or severity of adverse effects can be increased when Tolevamer is combined with Almasilate.
Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Almasilate.
Captopril Almasilate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefpodoxime The serum concentration of Cefpodoxime can be decreased when it is combined with Almasilate.
Cefuroxime The serum concentration of Cefuroxime can be decreased when it is combined with Almasilate.
Chloroquine Almasilate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Elvitegravir Almasilate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gabapentin enacarbil The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Almasilate.
Hyoscyamine Almasilate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rifampin Almasilate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mecamylamine Almasilate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Memantine Almasilate may decrease the excretion rate of Memantine which could result in a higher serum level.
Penicillamine Almasilate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Quinidine Almasilate may decrease the excretion rate of Quinidine which could result in a higher serum level.
Sulpiride The therapeutic efficacy of Sulpiride can be increased when used in combination with Almasilate.
Allopurinol The therapeutic efficacy of Allopurinol can be decreased when used in combination with Almasilate.
Fexofenadine Almasilate can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Raltegravir The serum concentration of Raltegravir can be decreased when it is combined with Almasilate.
Mesalazine Almasilate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cysteamine The bioavailability of Cysteamine can be decreased when combined with Almasilate.
Ketoconazole Almasilate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thiethylperazine Almasilate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promazine Almasilate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prochlorperazine Almasilate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlorpromazine Almasilate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Triflupromazine Almasilate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluphenazine Almasilate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioridazine Almasilate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Moricizine Almasilate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trifluoperazine Almasilate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perphenazine Almasilate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mesoridazine Almasilate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetophenazine Almasilate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promethazine Almasilate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alimemazine Almasilate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methotrimeprazine Almasilate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Periciazine Almasilate can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acepromazine Almasilate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aceprometazine Almasilate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pipotiazine Almasilate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioproperazine Almasilate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BL-1020 Almasilate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cyamemazine Almasilate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue Almasilate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
Propiopromazine Almasilate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perazine Almasilate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Butaperazine Almasilate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlorproethazine Almasilate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thiazinam Almasilate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dixyrazine Almasilate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perphenazine enanthate Almasilate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methenamine The therapeutic efficacy of Methenamine can be decreased when used in combination with Almasilate.
Doxycycline Almasilate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lymecycline Almasilate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clomocycline Almasilate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline Almasilate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Demeclocycline Almasilate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetracycline Almasilate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metacycline Almasilate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Minocycline Almasilate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarecycline Almasilate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Omadacycline Almasilate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Penimepicycline Almasilate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Triethylenetetramine Almasilate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Moxifloxacin Almasilate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Grepafloxacin Almasilate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enoxacin Almasilate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pefloxacin Almasilate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trovafloxacin Almasilate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic acid Almasilate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosoxacin Almasilate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cinoxacin Almasilate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lomefloxacin Almasilate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gatifloxacin Almasilate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norfloxacin Almasilate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levofloxacin Almasilate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gemifloxacin Almasilate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ofloxacin Almasilate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sparfloxacin Almasilate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Temafloxacin Almasilate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fleroxacin Almasilate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Technetium Tc-99m ciprofloxacin Almasilate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Garenoxacin Almasilate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nemonoxacin Almasilate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Flumequine Almasilate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3888581
    Authors unspecified: Magaldrate and almasilate--complex buffering antacids. Drug Ther Bull. 1985 May 20;23(10):39-40.
  • PMID: 11550076
    Ranade VV, Somberg JC: Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001 Sep-Oct;8(5):345-57.
  • PMID: 24100727
    Ford AC, Moayyedi P: Dyspepsia. Curr Opin Gastroenterol. 2013 Nov;29(6):662-8. doi: 10.1097/MOG.0b013e328365d45d.
  • PMID: 24459527
    Seo JW, Park TJ: Magnesium metabolism. Electrolyte Blood Press. 2008 Dec;6(2):86-95. doi: 10.5049/EBP.2008.6.2.86. Epub 2008 Dec 31.

Contoh Produk & Brand

Produk: 2 • International brands: 1
Produk
  • Ohtas Isan Antacid
    Tablet • - • Oral • US • OTC
  • Ohtas Isan Antacid
    Tablet • - • Oral • US • OTC
International Brands
  • Megalac

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul